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Abstract A fusion protein was constructed between the porcine 
rx2A-adrenoceptor and a pertussis toxin-insensitive (Cys351Gly) 
form of the a subunit of the G protein GÜ . Addition of agonist 
ligands to membranes of COS-7 cells transiently transfected to 
express this construct, and treated with pertussis toxin prior to 
cell harvest, resulted in stimulation of both high affinity GTPase 
activity and enhanced binding of [3 5S1GTPTS. By considering the 
fusion protein as an agonist-activated enzyme and measuring 
^max of GTP hydrolysis a range of agonist ligands displayed 
varying efficacy in their capacity to activate the receptor-
associated G protein with adrenaline = noradrenaline = rx-methyl-
noradrenaline > UK14304 > BHT933 > xylazine = clonidine. A 
similar rank order was observed following independent co-
expression of the a2A-adrenoceptor and Cys351Gly-Giia. These 
data demonstrate the utility and applicability of using a receptor-
G protein fusion protein approach, in which the stoichiometry of 
receptor and G protein is fixed at 1:1, to measure and further 
understand the nature of agonist efficacy. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
A molecular understanding of the nature of efficacy [1] of 
agonists at G protein-coupled receptors (GPCRs) remains a 
major challenge in GPCR biochemistry and pharmacology 
[2,3]. Furthermore, as measured estimates of efficacy can be 
shown to vary with tissue, with levels of expression of a re-
ceptor and potentially with the point within a signal trans-
duction cascade at which response is detected [4] then inherent 
problems exist in providing adequate and unambiguous meas-
urements. One of the earliest, and hence most direct points at 
which both function and efficacy might be estimated is at the 
stimulation of the G protein which interacts with a receptor. 
This may be achieved using assays which measure the ex-
change of GDP for GTP and/or the subsequent hydrolysis 
of GTP induced by agonist ligands. This is often constrained, 
however, by a general lack of information on the absolute 
levels of expression of the receptor and its cognate G protein 
and their disposition in relation to one another within cells 
and at the plasma membrane. To overcome these problems we 
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have generated a fusion protein between the porcine 0C2A-adre-
noceptor [5] and a pertussis toxin-insensitive (Cys351Gly) mu-
tant of the a subunit of the G protein Gnoc [6]. This defines 
the stoichiometry of expression of the GPCR and G protein 
as 1:1 and necessitates their proximity following expression. 
Following transient expression in pertussis toxin-treated COS-
7 cells addition of the c<2-adrenoceptor agonist UK14304 re-
sults in stimulation of high affinity GTPase activity, demon-
strating the functionality of this construct [7]. We have also 
demonstrated that creation of fusion proteins between the 
ot2A-adrenoceptor and acylation-deficient forms of Gad can 
act to rescue the lack of functional interactions following in-
dependent co-expression of these proteins [8]. Herein, we use 
this construct to evaluate the efficacy of a number of agonists 
at this GPCR by measuring the ligand-induced rate of GTP 
turnover by the physically associated G protein. We demon-
strate that agonist ligands display a range of efficacy at this 
construct and that a similar rank order of efficacy is obtained 
following co-expression of the separated receptor and G pro-
tein. We suggest that this strategy may be widely applicable to 
the designation of efficacy of agonist ligands for specific 
GPCR-G protein tandems. 
2. Materials and methods 
2.1. Materials 
All materials for tissue culture were supplied by Life Technologies, 
Inc. (Paisley, Strathclyde, Scotland, UK). [3H]RS-79948-197 (90 Ci/ 
mmol) was purchased from Amersham International. [y-32P]GTP 
(30 Ci/mmol) and [35S]GTPyS (1100 Ci/mmol) was obtained from 
DuPont/NEN. Pertussis toxin (240 μg/ml) was purchased from Spey-
wood. All other chemicals were from Sigma or Fisons pic and were of 
the highest purity available. Oligonucleotides were purchased from 
Genosys (Cambridge, UK). 
2.2. Construction of Cys351 Gly-GuU 
A pertussis toxin-resistant form of rat Сца was generated [6] fol-
lowing excision of the wild-type sequence on an EcoRi restriction 
fragment from the vector pGEM2 and insertion into the EcoRl site 
of pBluescript KS~ (pBS) (Stratagene) creating pBS/Gna. To gener-
ate pBS/Gi!(Cys351Gly) the 3' 44 base pairs (bp) of the Gua open 
reading frame (ORF) and the 3' flanking sequence was excised from 
pBS/G;iCC upon digestion with restriction enzymes Aatll and Hindlll, 
and replaced with the synthetic oligonucleotide linker created follow-
ing annealing of the oligonucleotides 5'-CATCATAAAGAATAACC-
TAAAAGACGGTGGTCTCTTCTAAGAATTCA-3' and 5'-AGCT-
TGAATTCTTAGAAGAGACCACCGTCTTTTAGGTTATTCTTT-
ATGATGACGT-3' (Cys351Gly in bold; restriction sites for £coRI, 
ffiradlll and Aatll sites underlined) to recreate the 3' end of Gjia. The 
vector was sequenced following cloning to demonstrate the presence 
of the cysteine to glycine mutation and the authenticity of the 3' end 
of the GÜ a open reading frame. 
2.3. Construction of the agA-adrenoceptor-Cys351Gly-G,ia fusion 
construct 
The porcine агА-adrenoceptor [5] was obtained from Dr. L.E. Lim-
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bird, Vanderbilt University, TN. The pertussis toxin-resistant 
Cys361Gly form of rat G;ia was linked to the a2A-adrenoceptor. 
To do so, the open reading frame (ORF) of the a2A-adrenoceptor 
cDNA was amplified by PCR using the oligonucleotides: sense 
5'-TTGGTACCATGTATCCTTACGACGTTC-3', antisense 5'-AA-
GAATTCCATGGCGATCCGTTTCCTGTCCCCACGGC-3' (re-
striction sites for Kpnl, EcoRl and Ncol are underlined). The PCR 
amplified fragment was digested with Kpnl and EcoRl and ligated to 
pBluescript through these restrictions sites. Introduction of the Ncol 
site at the 3' end of the ORF resulted in the C-terminal amino acid of 
the receptor being altered from Val to Ala and removal of the stop 
codon. The rat Cys351Gly-Giia cDNA contains two Ncol sites; one 
straddling the ATG start codon and the other 268 bp downstream 
from this. This 268 bp fragment was removed from Cys351Gly-Giia in 
pBS by digestion with Ncol and the remaining Cys351Gly-GiiOC pBS 
cDNA was religated. The shortened cDNA was excised from pBS 
with EcoRI and cloned into the EcoRl site of the a2A-adrenoceptor 
in pBS, adjacent to the 3' end of the receptor ORF. The 268 bp 
fragment was then inserted between the Ncol sites at the 3' end of 
the a2A-adrenoceptor ORF and at the 5' end of the Cys351Gly-G;ia 
ORF. This resulted in production of an in-frame construct whereby 
the 3' end of the a2A-adrenoceptor ORF was exactly adjacent to the 
5' end of the Cys351Gly-Güa ORF. The full fusion construct was then 
excised from pBS with Kpnl and EcoRl and ligated into the eukary-
otic expression vector pCDNA3 (Invitrogen). 
2.4. Cell culture and transfection 
COS-7 cells were maintained in DMEM containing 10% (v/v) new-
born calf serum (NCS), 2 mM L-glutamine, 100 units/ml penicillin and 
100 μg/ml streptomycin. Cells were seeded in 60 mm culture dishes 
and grown to 60-80% confluency (18-24 h) prior to transfection with 
pCDNA3 containing the relevant cDNA species using lipofectamine 
reagent (Life Technologies, Inc.). For transfection, 2.5-2.8 μg of 
DNA was mixed with 10 μΐ of lipofectamine in 0.2 ml of Opti-
MEM (Life Technologies, Inc.) and incubated at room temperature 
for 30 min prior to the addition of 1.8 ml of Opti-MEM. COS-7 cells 
were exposed to the DNA/lipofectamine mixture for 5 h. Two ml of 
20% (v/v) NCS in DMEM was then added to the cells. Cells were 
harvested 48 h after transfection. 24 h before harvest they were treated 
with pertussis toxin (50 ng/ml) to case complete ADP-ribosylation of 
the a subunits of endogenously expressed Gj-family G proteins [6]. 
2.5. Preparation of membranes 
Plasma membrane-containing P2 particulate fractions were pre-
pared from cell pastes that had been stored at —80°C following har-
vest. Cell pellets were resuspended in 0.5 ml of 10 mM Tris-HCl, 
0.1 mM EDTA, pH 7.5 (buffer A) and rupture of the cells was 
achieved with 50 strokes of a hand-held Teflon on-glass homogenizer 
followed by passage (10 times) through a 25-gauge needle. Cell lysates 
were centrifuged at lOOOXg for 10 min in a Beckman TJ-6 centrifuge 
to pellet the nuclei and unbroken cells and P2 particulate fractions 
were then recovered by centrifugation of the supernatant at 
200 000 Xg for 30 min in a Beckman Optima TLX ultracentrifuge 
using a Beckman TLA 100.2 rotor. P2 particulate fractions were re-
suspended in buffer A and stored at —80°C until required. Protein 
concentrations were determined using the bicinchoninic acid (BCA) 
procedure using BSA as standard. 
2.6. [sH]RS-79948-197 binding studies 
Binding assays were initiated by the addition of 5-10 μg of protein 
to an assay buffer (10 mM Tris-HCl, 50 mM sucrose, 20 mM MgCl2, 
pH 7.5) containing [3H]RS-79948-197 [9] (0-1 nM). Non-specific bind-
ing was determined in the presence of 100 μΜ idazoxan. Reactions 
were incubated at 30°C for 45 min, and bound ligand was separated 
from free by vacuum filtration through GF/C filters. The filters were 
washed with 3 X 5 ml of assay buffer, and bound ligand was estimated 
by liquid scintillation spectrometry. 
2.7. High affinity GTPase assays 
These were performed essentially as described in [10] with Vmsx 
estimates being obtained following transformation of enzyme velocity 
vs. substrate (GTP) concentration experiments as described in [7]. 
Non-specific GTPase was assessed by parallel assays containing 
100 μΜ GTP. 
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2.8. Agonist regulation of [35S]GTPyS binding 
Binding studies were performed essentially as in [11,12]. Typically, 
membranes (5 μg) were incubated at 30°C for 30 min in a final volume 
of 100 μΐ of reaction mixture comprising 20 mM HEPES-NaOH, 
pH 7.4, 3 mM MgCl2, 100 mM NaCl, 0.2 mM ascorbate, 10 μΜ 
GDP, 5 nM [35S]GTPyS (~350 nCi) in the presence or absence of 
agonist as described in the text. The non-specific binding component 
was determined by inclusion of G T P T S to a final concentration of 
100 μΜ. The incubation was terminated by addition of 2.5 ml of 
ice-cold washing buffer comprising of 20 mM HEPES-NaOH, pH 
7.4 and 3 mM MgCl2 and rapid filtration through Whatman GF/C 
filters followed by three washes (5 ml) with ice-cold wash buffer. 
Filters were air-dried, dissolved in 5 ml ULTIMA-Gold XR scintillant 
(Packard), left overnight and counted on a Beckman LS-6500 liquid 
scintillation analyser. All assays were performed in triplicate. 
3. Results 
The a 2A-adrenoceptor-Cys3 5 1Gly-Güa fusion protein was 
expressed transiently in COS-7 cells. Expression of this poly-
peptide (between 6-15 pmol/mg membrane protein in individ-
ual transfections) was detected by the specific binding of the 
high affinity (Kd = 0.41 ± 0.05 n M , mean ± S.E.M., n = 11) and 
highly a2-adrenoceptor selective antagonist [3H]RS-79948-197 
(Fig. 1). Immunoblot t ing with the Guoc specific antiserum I1C 
also allowed detection of an approx. 100 k D a polypeptide 
only in membranes of transfected cells (data not shown but 
see [7,8]). In all experiments, prior to harvest, the cells were 
treated with pertussis toxin (50 ng/ml, 24 h) to eliminate any 
potential interactions between the receptor element of the 
expressed fusion protein and the endogenously expressed 
Gi-family G proteins [6]. We have shown previously that 
such pertussis toxin treatment is sufficient to cause complete 
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Fig. 1. Expression of an a2A-adrenoceptor-Cys351Gly-Giia fusion 
protein. P2 particulate membrane fractions of pertussis toxin-treated 
COS-7 cells transfected with the a2A-adrenoceptor-Cys351Gly-Gia 
cDNA were subjected to saturation binding studies using [3H]RS-
79948-197 (upper panel) as described in Section 2. Specific binding 
is displayed. This data was then converted to a Scatchard plot (low-
er panel). Similar studies were performed on all the individual trans-
fections used in these studies (see Section 3 for details). 
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Fig. 2. Agonist-mediated stimulation of [35S]GTPyS binding to 
0C2A-adrenoceptor-Cys351Gly-Gii0C. The ability of varying concentra-
tions of adrenaline (filled triangles), noradrenaline (open circles) and 
UK14304 (filled squares) to stimulate the binding of [35S]GTPvS 
was measured, as described in Section 2, in membranes of pertussis 
toxin-treated COS-7 cells transfected to express the a2A-adrenocep-
tor-Cys351Gly-GiiOc fusion protein. Results are presented as mean-
s ± error using membranes derived from three separate transfections. 
ADP-ribosylation of the entire endogenous cellular popula-
tion of Gj-like G proteins. Such treatment prevents agonist 
stimulation of high affinity GTPase activity following expres-
sion of the porcine 0C2A-adrenoceptor in combination with 
wild-type G ì a but not with Cys351Gly-Güa [6]. 
Agonist stimulation of specific binding of [35S]GTPyS to 
membranes of COS-7 cells could be measured following per-
tussis toxin treatment of cells transfected to express the 
a2A-adrenoceptor-Cys351Gly-Giia fusion protein (Fig. 2) but 
not in mock transfected cells (data not shown). This was 
achieved in a concentration-dependent manner (Fig. 2) with 
EC50 values for adrenaline (7.9 ± 1.0 X IO -7 M), noradrenaline 
(3.9Ì0.2X10"6 M) and UK14304 (3.7 ± 0.2 X IO"8 M) 
(means ± S.E.M., n = 3). Although we had previously used 
UK14304 to demonstrate the functionality of the tX2A-adreno-
ceptor-Cys351Gly-Giia fusion protein [7,8], the current studies 
demonstrated UK14304 to function as a partial agonist in 
comparison to adrenaline with estimated efficacy of some 
50-60% of the endogenous ligand. The agonist-induced in-
crease in specific binding of [35S]GTPyS was sufficiently low 
in absolute terms, however, to limit its potential usefulness in 
further efficacy estimates. This may reflect that the stoichiom-
etry of the proteins integrated into the fusion protein defines 
that a maximum of one G protein can be labelled per receptor 
binding site occupied. This would limit the theoretical label-
ling potential to one mol [35S]GTPyS per mol of 0C2A-adreno-
ceptor-Cys351Gly-GiiOc fusion protein. To overcome this prob-
lem we utilised high affinity GTPase activity measurement as 
an assay which conceptually can function as an accumulation 
assay over time. In membranes of pertussis toxin-treated, 
a2A-adrenoceptor-Cys351Gly-Giia fusion protein expressing 
COS-7 cells basal high affinity GTPase activity continued in 
a linear fashion over at least 75 min (Fig. 3). Addition of 
adrenaline or noradrenaline (1 X IO -4 M) stimulated this ac-
tivity. The effect of the agonists was also linear throughout at 
least a 60 min incubation (Fig. 3) and thus this period was 
selected for all further studies. 
Concentration effect curves for noradrenaline stimulation of 
high affinity GTPase activity resulted in an EC50 of 
9.7 ± 5.3 X 10"6 M (mean ± S.E.M., n - 3). Concurrent concen-
tration effect curves performed on the same membrane prep-
arations with UK14304 resulted in a measured EC50 of 
Time (min) 
Fig. 3. Time course of basal and agonist-stimulated high affinity 
GTPase activity in cells expressing ot2A-adrenoceptor-Cys351Gly-
GiiOC. High affinity GTPase activity was measured at various times 
in membranes of pertussis toxin-treated COS-7 cells transfected to 
express the 0C2A-adrenoceptor-Cys351Gly-Gji0t fusion protein in the 
absence of ligand (open symbols) or in the presence of 1 X IO-4 M 
noradrenaline (filled symbols). Similar results were obtained in three 
further experiments. 
2.4±0.2X10"7 M (meaniS.E.M, n = 3). However, it was 
again noticeable that UK14304 acted as only a partial agonist 
compared to noradrenaline (Fig. 4). A range of a2A-adreno-
ceptor active ligands were compared to noradrenaline for their 
capacity to stimulate GTPase activity of the ot2A-adrenocep-
tor-Cys351Gly-Gjia fusion protein tethered G protein. Of 
those examined, only adrenaline (EC50 = 3.2±0.5X IO -6 M) 
and α-methylnoradrenaline (EC50 = 5.5±0.6x 10~6 M) (Fig. 
4 and Table 1) also functioned as full agonists with xylazine, 
BHT933 and clonidine all functioning as partial agonists (Fig. 
4 and Table 1). For comparison individual cDNAs encoding 
the ot2A-adrenoceptor and Cys351Gly-Gjia were co-expressed 
in COS-7 cells and the efficacy of the same series of agonists 
again assessed following pertussis toxin treatment of the cells 
(Table 1). All of the ligands shown to be partial agonists at 
the a2A-adrenoceptor-Cys351Gly-Gii0c fusion protein were also 
partial agonists in comparison to adrenaline for the separated 
receptor and G protein (Table 1). Although the rank order of 
efficacy was not different in the two receptor systems exam-
ined, the absolute efficacy of all of the partial agonists was 
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Fig. 4. Efficacy measurement of ligands at the a2A-adrenoceptor-
Cys351Gly-GiiOC fusion protein. The capacity of varying concentra-
tions of adrenaline (filled triangles), noradrenaline (open squares), 
UK14304 (filled squares), xylazine (open triangles), BHT933 (open 
circles) and clonidine to stimulate the high affinity GTPase activity 
of the 0t2A-adrenoceptor-Cys351Gly-Gü0[ fusion protein was assessed 
following its expression in COS-7 cells and pertussis toxin pretreat-
ment of the cells. Data are presented as the % of the stimulation 
produced by 1X IO-4 M adrenaline. Results are means from three 
independent experiments. 
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Fig. 5. Partial agonism at the a2A-adrenoceptor-Cys361Gly-G;ia fu-
sion protein is manifest in varying values for the Kmax of the 
GTPase activity without alteration in Km for GTP. High affinity 
GTPase activity was measured at varying concentrations of GTP 
(upper panel) in membranes of pertussis toxin-treated COS-7 cells 
transfected to express the a2A-adrenoceptor-Cys351Gly-Giia fusion 
protein in the absence of ligand (filled circles) or in the presence of 
1X 10~4 M adrenaline (filled triangles), α-methylnoradrenaline (open 
circles), UK14304 (filled squares) or xylazine (open triangles). The 
data were then transformed as a Eadie-Hofstee plot (lower panel) to 
allow direct estimation of Vmsx, Km for GTP and the efficacy of the 
ligands compared to adrenaline. Similar results were obtained in 
three further experiments. 
greater when examining the separate receptor and G protein 
compared to the cC2A-adrenoceptor-Cys351Gly-GiiOC fusion 
protein (Table 1). 
Standard high affinity GTPase activity assays, such as those 
above, are routinely performed with substrate (GTP) concen-
trations in the region of 5 X 10~7 M [9]. To assess if the meas-
ured differences in efficacy between adrenaline, oc-methylnor-
adrenaline, UK14304 and xylazine truly reflected differences 
in the enzymic capacity of the a2A-adrenoceptor-Cys351Gly-
Gjicc fusion protein when the agonist ligand binding site 
was occupied with these ligands, maximal GTP hydrolysis 
rates were measured. By treating the 0C2A-adrenoceptor-
Cys351Gly-Gua f u s j o n protein as an agonist-activated en-
zyme, assessment of GTP hydrolysis at varying concentrations 
of GTP (Fig. 5) could be used to assess Fmax of the construct 
induced by differing agonists. Such data confirmed that xyla-
zine and UK14304 functioned as partial agonists compared to 
adrenaline and a-methylnoradrenaline. As such, the partial 
agonist effects recorded when using a single concentration of 
GTP as substrate were not a reflection of distinct agonist-
induced variations in the Km of the construct for GTP 
(Fig. 5) (Km for basal GTPase activity = 3.2 ±0.2 X 1(Г7 М 
and in the presence of UK14304 (1X10"5 M) = 
3.7±0.4Xl(T7 M, means ± S.E.M., и = 9 in each case) as 
this was not altered substantially by the identity or efficacy 
of the agonist. 
4. Discussion 
Agonist efficacy is a measure of the capacity of a ligand to 
induce a functional response [1-3]. Although often viewed 
simply as the 'strength' of the agonist, in molecular terms 
this can be considered as the capacity of a ligand to maintain 
or induce a GPCR conformation capable of activating a cog-
nate G protein and thus to subsequently regulate downstream 
effectors. Assessment of the efficacy of an agonist at a GPCR 
can thus be measured at a variety of levels within the signal 
transduction cascade ranging from GPCR-G protein interac-
tion to second messenger production or final physiological 
response. However, as G protein-coupled systems provide 
an amplification cascade, assessment of agonist efficacy can 
vary dependent upon the point of measurement and with al-
terations in levels of expression of individual protein compo-
nents of the cascade [4,13]. For example, we have recently 
demonstrated increases in partial agonist efficacy with increas-
ing levels of expression of the ß2-adrenoceptor in NG108-15 
cells, as measured by the ability of the ligands to cause stim-
ulation of adenylyl cyclase activity [4]. This is a reflection that 
the cellular levels of adenylyl cyclase represent the quantita-
tively limiting element in the cascade leading from GPCR via 
Gscc to adenylyl cyclase [13]. Furthermore, in situations in 
which a GPCR has the capacity to activate multiple G pro-
teins leading to regulation of multiple second messengers [14] 
then differences in efficacy [15] and even of rank order of 
potency of agonist ligands have been described for the two 
Table 1 
Ligand Efficacy to activate 
a2A-adrenoceptor—Cys351Gly-Giia a2A-adrenoceptor+Cys351Gly-Giia 
(% of adrenaline) (% of adrenaline) 
Adrenaline 
Noradrenaline 
a-Methylnoradrenaline 
UK 14304 
BHT933 
Xylazine 
Clonidine 
100 
97.011.8 (5) 
104.9 ±4.9 (3) 
56.3 ±2.0 (7) 
19.8 ±1.7 (5) 
16.1 ±2.7 (7) 
14.5 ±1.2 (2) 
100 
98.7 ±1.3 (3) 
93.0 ±3.9 (3) 
85.3 ±2.5 (3) 
44.2 ±1.8 (3) 
28.0 ±3.1 (3) 
26.0 ±5.3 (3) 
The capacity of maximally effective concentrations of ligands with known agonist activity at ci2-adrenoceptors to stimulate high affinity GTPase 
activity of the 0C2A-adrenoceptor—Cys351Gly-Giioe fusion protein or of the oi2A-adrenoceptor plus Cys351Gly-Giia was assessed following their 
transient expression in COS-7 cells. 
Efficacy was determined relative to the function of adrenaline (1 X Ю-4 М) in parallel assays. 
Data represent means ± S.E.M. and the values in parentheses indicate the number of independent experiments performed with each ligand. 
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functions [16-18]. Such a scenario has been described as re-
ceptor channelling [19,20]. Given such observations it is im-
portant to try to devise means by which measurements of 
ligand efficacy should not be hostage to such events because 
such pharmacology is often considered an indicator of the 
potential presence of multiple receptor subtypes. Given a large 
literature on the pharmacology and function of 0C2-adrenocep-
tors (see [21,22] for reviews) we selected the ci2A-adrenoceptor 
for analysis. 
We have recently produced a fusion protein between the 
porcine a2A-adrenoceptor and the a subunit of the G protein 
Gii by simply linking together the C-terminal tail of the re-
ceptor and the N-terminus of the G protein [7]. To allow ease 
of analysis this was constructed using a modified form of the 
G protein in which Cys351 was modified to Gly [6]. Cys351 is 
the normal acceptor site on the G protein a subunit for ADP-
ribose transferred by the ADP-ribosyltransferase activity of 
pertussis toxin. ADP-ribosylation prevents productive infor-
mation transfer between an agonist-occupied GPCR and the 
G protein [23]. As such, any potential interactions between the 
agonist-occupied fusion protein and the endogenous popula-
tion of Gj-like G proteins could be prevented, allowing regu-
lation of the attached G protein to be studied in situ following 
expression of the fusion protein and treatment of the cells 
with pertussis toxin. Introduction of the Cys351 Gly mutation 
into G;i a reduces the potency of the UK14304-occupied 
a2A-adrenoceptor to activate the G protein [6]. Using this 
fusion protein we have shown previously that addition of 
the a2-adrenoceptor agonist UK.14304 results in an increase 
in GTPase activity of the attached G protein [7,8]. 
In the current studies we have extended this analysis to a 
variety of ligands which display agonist properties at the 
0C2A-adrenoceptor. We demonstrate that variation in agonist 
efficacy at the oi2A-adrenoceptor-Cys351Gly-GjiOc fusion pro-
tein can be assayed at one of the most proximal points of 
measurement available, i.e. guanine nucleotide exchange and 
hydrolysis, as variation in GTP turnover rate and hence in 
Pmax °f the construct (Fig. 5). Initial experiments demon-
strated greater hydrolysis of GTP by the oi2A-adrenoceptor-
Cys351Gly-Güa f u s i o n protein by maximally effective concen-
trations of noradrenaline compared to UK14304 (Fig. 4), sug-
gesting UK 14304 to function as a partial agonist at this con-
struct. Variation in measured efficacy was subsequently 
observed for a variety of ligands, with the endogenous ago-
nists adrenaline and noradrenaline along with a-methylnora-
drenaline all being equally and maximally efficacious (Table 
1). By contrast, xylazine, BHT933 and clonidine were only 
weakly active with efficacy values in the region of 20% of 
those of the endogenous ligands. Although it is difficult to 
envisage conceptually, we wished to demonstrate that the 
measured variation in efficacy between ligands did not repre-
sent differences in the affinity of the G protein within the 
ligand bound fusion protein to bind GTP. Initial experiments 
were all performed (as are most high affinity GTPase assays) 
at a single subsaturating concentration of GTP. Measurement 
of the rate of GTP hydrolysis in response to maximally effec-
tive concentrations of the agonists was thus performed at 
various GTP concentrations. This confirmed that the Km for 
GTP of the oi2A-adrenoceptor-Cys351Gly-Giia fusion protein 
was not modified by the identity of the ligand. As such, the 
agonist-induced Kmax provided a direct measurement of ligand 
efficacy (Fig. 5). 
The results presented provide the first evidence that a chi-
maeric GPCR-G protein fusion protein can provide a novel 
means to measure agonist efficacy at a GPCR. The fixed 1:1 
stoichiometry of the GPCR and G protein within the fusion 
protein further defines an estimate of ligand efficacy which 
should be independent of levels of receptor and G protein 
expression, two elements which can vary widely in different 
tissues. Also, as it should be possible to generate fusion pro-
teins between a receptor and different G protein oc subunits, 
we suggest that fusion proteins such as used herein may pro-
vide a means to determine efficacy values for agonist ligands 
for specific combinations of GRCR and G protein. Further-
more, the capacity to quantitate levels of expression of the 
fusion protein by saturation [3H]ligand binding studies (Fig. 
1) defines the total number of G proteins which can become 
activated at receptor saturating concentrations of agonist li-
gand and thus allows direct estimation of GTP turnover num-
ber [7] in response to differing agonists. 
One concern with the approach employed is that the phys-
ical linkage of the G protein to the GPCR might limit or 
constrain the capacity of agonist ligands to induce GPCR 
conformations capable of resulting in guanine nucleotide ex-
change and G protein activation. We thus also measured effi-
cacy of the same series of ligands following the separate co-
expression of the 0C2A-adrenoceptor and Cys351Gly-Giia. 
Although this resulted in increased estimates of efficacy of 
all of the partial agonists when compared to adrenaline, the 
rank order of efficacy was unchanged between the fusion pro-
tein and the separated receptor and G protein (Table 1). In 
these experiments, however, we are unable to quantitate the 
relative levels of GPCR and G protein expression. Further-
more, there is no way to define the number of copies of the G 
protein activated per receptor. 
Interestingly, a variety of experiments have suggested that a 
'pre-coupled' state may exist for аг-adrenoceptors and G pro-
teins [20,24] and the fusion protein construct used herein may 
inherently represent a 'pre-coupled' state. Equally, little is 
known about possible constraints placed in GPCR-G protein 
interactions in more native states by cellular location [25] and 
potential roles for the cytoskeleton [26,27] for example. Many 
experiments have indicated the capacity of a range of GPCRs 
to interact with multiple co-expressed G protein (see [14] for 
review). Recent evidence has suggested that certain agonists 
may 'channel' responses due to variations in potency and 
efficacy to promote or stabilise interactions of GPCRs with 
different individual G proteins (see [19] for review). It is in-
teresting in this regard that although following expression of 
the a2A-adrenoceptor in CHO cells Eason et al. [15] were able 
to demonstrate that all of the ligands they tested (many of 
which were thus deliberately used in this study) acted as full 
agonists to promote inhibition of adenylyl cyclase (via Q ) , 
these ligands displayed a range of efficacy for activation of 
adenylyl cyclase (via Gs). As such, a means to separate and 
study agonist efficacy at individual GPCR-G protein contacts 
is clearly required. It will be of considerable interest, in time, 
to assess the efficacy of a range of ligands at an oc2A-adreno-
ceptor-Gsa fusion construct akin to the fusion protein used 
herein. 
These studies provide for the first time a novel approach to 
the measurement of ligand efficacy and potentially their effi-
cacy at specific GPCR-G protein tandems by fixing the recep-
tor and G protein stoichiometry in a system and, by their 
146 A. Wise et al.lFEBS Letters 419 (1997) 141-146 
physical attachment, defining their proximity. We anticipate 
that this strategy will be widely applicable. 
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